GSK reported a robust performance for 2023 on Wednesday, backed by broad-based growth across its segments, as it also revised its growth projections for the future.
(Bloomberg) Runaway demand for Novo Nordisk A/S’s diabetes and weight-loss drugs has propelled the Danish drugmaker into a class all its own atop Europe’s pharmaceutical sector — and the Stoxx Europe 600 Index — so achieving its 2023 targets should be a shoo-in when it reports next week.Most Read from BloombergPutin Sends US Signal on Ukraine Talks, Seeing War AdvantageUS Extends Lead Over China in Race for World’s Biggest EconomyTesla Sinks After Warning About ‘Notably Lower’ Growth RateJPMo